Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 16, 2025

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas

View Full Paper
Ask AI
Bookmark
Share

Authors

TCTamrin ChowdhuryCTC. Mircea S. TesileanuEKEmre Kocakavuk

Discussion

Loading...

Member takes

Overview

Whole-genome sequencing shows distinct genetic alterations in astrocytomas and oligodendrogliomas, indicating treatment responses differ.

Key Points

  • IDH-mutant gliomas include astrocytomas and oligodendrogliomas, diagnosed between ages 30-50.
  • Newly acquired point mutations in recurrent oligodendrogliomas were linked to higher mutation rates.
  • Multi-timepoint whole-genome sequencing of 206 patient samples revealed unique genetic alterations in response to therapy.
  • Distinct mutational signatures suggest divergent DNA damage responses in astrocytomas and oligodendrogliomas after treatment.

Cite This Study

Chowdhury et al. (2025) studied this question.

synapsesocial.com/papers/689a02c3e6551bb0af8ccaa8https://doi.org/10.1101/2025.07.11.664189
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Acquired genetic and cell-state changes in IDH-mutant glioma progression2026 · 7 citations
  2. 2Abstract A061: Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses2026
  3. 3Data from The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen2024
  4. 4Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling2025
  5. 5Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling2024 · 3 citations